ANTX News

Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. Seven biotechs have gone public so far in 2022. While the group performed relatively well in the first quarter, returns...read more

The IPO market stayed relatively quiet, with only one IPO and one SPAC pricing this past week. Pipeline activity maintained its slow pace, with only two small IPOs and one SPAC submitting initial filings. AN2 Therapeutics (ANTX) priced its upsized IPO at the midpoint to raise $69 million at a $296 million market cap. The company is developing an in-licensed...read more

AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, raised $69 million by offering 4.6 million shares at $15, the midpoint of the $14 to $16 range. The company offered 0.6 million (15%) more shares than anticipated. Its initial candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous...read more

AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, announced terms for its IPO on Monday. The Menlo Park, CA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, AN2 Therapeutics would command a fully diluted market value of $287 million. The...read more